Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in Sporadic Colorectal Adenomas and Colorectal Cancer
NCT03796884Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2019
- Primary completion
- Nov 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) and Colorectal Adenoma (CRA) comparing Arm I (linaclotide) with Arm II (placebo) (2 arms). Primary endpoint: Pharmacodynamics effect on cGMP levels at 2 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
linaclotide
03
Conditions
colorectal cancer (CRC)Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT03796884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796884.